FDA+ channel feed – Endpoints News

FDA+ channel feed

FDA open to use of new MRD endpoint ahead of advisory committee meeting

Last year

Endo sues FDA over its handling of generic Adrenalin approvals

Last year

Exclusive: Top lobbyist at BIO leaves as trade group grapples with US-China tensions

Last year

Novartis, Sanofi and PhRMA push FDA on how to better handle complex trial designs

Last year

Virginia governor vetoes bill to create advisory board to reduce drug prices

Last year

Indian pharma receives FDA warning letter for barefoot employees and general 'disrepair'

Last year

BrainStorm outlines plans for what may be final attempt to bring ALS drug to market

Last year

FDA officials raise concerns with immunotherapy overuse for early-stage cancer patients: #AACR24

Last year

Nearly half of cancer drugs granted accelerated approval didn’t end up showing clinical benefit — study

Last year

Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug

Last year

FDA issues second CRL to Supernus for Parkinson's drug-device combo

Last year

FDA approves J&J and Legend’s Carvykti for second-line multiple myeloma

Last year

FDA grants Enhertu tumor-agnostic accelerated approval

Last year

Loosening Medicaid restrictions on hep C drugs could improve patient access, study finds

Last year

Bristol Myers and 2seventy win label expansion for Abecma in earlier multiple myeloma

Last year

Paxlovid didn’t shorten Covid symptoms in vaccinated adults, full trial results confirm

Last year

FDA approves Basilea’s antibiotic for severe bacterial infections

Last year

WuXi builds out lobbying bench amid legislative effort to blacklist company

Last year

'We beat big pharma': Biden applauds IRA, calls for expansion of Medicare negotiations

Last year

Almost all doses of Mounjaro, Zepbound in short supply through Q2

Last year

Congress' China hawks seek to add biotech suppliers to Pentagon warning list

Last year

CBER's Marks points to stockpiles of H5N1 vaccine as officials monitor reported human case

Last year

BMS' confirmatory trial of Krazati hits primary endpoint following 2022 accelerated approval

Last year

FDA delays decision on Applied Therapeutics’ rare metabolic disease drug

Last year

First page Previous page 27 28 293031 32 33 Next page Last page